2.4 Systemic Healing Factors and Medications

2.4 Systemic Healing Factors and Medications

Quick Answer: Dressings cannot outrun ischemia, uncontrolled glucose, nicotine, high-dose steroids, or starvation. Name the systemic factor, treat it as part of wound care, and if it cannot be reversed, call the wound not-healable and protect rather than promise closure.

010102 (factors affecting wound healing) and 010309 (medications) are the host chapter of the focused exam. A perfect topical plan on a foot with an ankle-brachial index of 0.4 is a delay to vascular referral.

Comorbidities that change healability

Diabetes and hyperglycemia. High glucose impairs neutrophil chemotaxis and phagocytosis, stiffens vessels via glycation, and travels with neuropathy and PAD. An A1C of 11% is not background color on the problem list; it is a wound-bed toxin. Glycemic control is a wound intervention—as much as offloading a plantar ulcer. You still individualize targets in frail elders, but you do not ignore random glucoses of 300 mg/dL because a silver dressing was applied.

Peripheral artery disease (PAD / LEAD). Macrovascular inflow failure produces punched-out, poorly granulating ulcers, claudication or rest pain, and a wound that will not fill. Local angiogenesis cannot compensate for an occluded tibial artery. Revascularization, when possible, is the healing plan; topical therapy is protection until then.

Venous disease. Chronic venous hypertension produces edema that widens capillary gaps, deposits fibrin, and starves skin of oxygen despite palpable pulses. Compression (when arterial inflow allows) is systemic-factor treatment delivered at the limb.

Heart failure. Biventricular failure drives dependent edema, poor forward flow, and sometimes cachexia. Aggressive compression without a heart-failure plan can dump fluid centrally. The stalled leg ulcer may be a cardiac problem wearing a dressing.

COPD and tissue oxygenation. Hypoxemia, steroid courses, and smoking cluster here. Fibroblasts and neutrophils are oxygen-hungry. A sat of 86% on room air is a healing factor, not only a pulmonary one. Tissue oxygenation also falls with anemia, edema, and vasoconstriction.

CKD. Uremia, anemia of chronic disease, calcium-phosphate disorders, and protein-intake limits collide with wound protein needs. You coordinate with nephrology rather than blindly ordering 1.5 g/kg protein in a dialysis patient without a plan. Calciphylaxis, when present, is an atypical systemic wound, not a missed Stage 2.

Anemia. Low oxygen-carrying capacity slows every aerobic repair step. Iron deficiency from chronic drainage is common in large ulcers; transfusion thresholds remain a medical decision, but the CWCN flags the hemoglobin as relevant.

Autoimmune disease. Vasculitis, rheumatoid disease, and scleroderma produce atypical ulcers and are treated with immunosuppression that then impairs repair. Pyoderma gangrenosum is a pathergy problem: aggressive wide debridement can enlarge it. Systemic diagnosis first.

Cancer and immunosuppression. Tumor burden, malnutrition, chemotherapy, radiation-damaged microvasculature, and drugs such as transplant immunosuppressants all blunt proliferation. Neutropenia changes infection risk and culture urgency.

Age, mobility, smoking, oxygen

Age slows inflammation and thins dermis (section 2.1); it is a factor, not a reason to withhold indicated care. Mobility and activity determine pressure, shear, and calf-muscle-pump function. A patient who will not or cannot leave the chair is a venous and pressure problem at once. Smoking and nicotine (cigarettes, some vaping, nicotine replacement still delivers nicotine) cause cutaneous vasoconstriction, increase carbon monoxide, impair fibroblast function, and raise platelet stickiness. Nicotine cessation is wound therapy. Tissue oxygen is the common pathway: if the host cannot deliver O₂, granulation will not appear no matter which foam you chose.

Medications that impair healing or change procedures

Topical steroids on intact periwound skin for dermatitis are not the same as pharmacologic systemic steroids, but chronic potent topical steroids still thin local dermis.

Not-healable until the host is addressed

Wound-care programs often sort wounds as healable, maintenance, or non-healable (sometimes called palliative or non-healable ischemic). A CWCN should be able to say: this ulcer will not close until inflow is restored, glucose is treated, calories are available, or the antiangiogenic agent and high-dose steroid are modified—if they even can be. Until then, goals are odor and exudate control, pain, infection surveillance, pressure relief, and avoiding harmful debridement of ischemic eschar that is a biologic dressing.

Calling a wound not-healable is not nihilism. It stops the cycle of weekly sharp debridement into dry gangrene and the family promise that the new collagen dressing will grow a pulse.

Scenario. Ms. Chen, 68, has an ischemic heel ulcer, ABI 0.45, A1C 11.2%, continues to smoke, takes prednisone 20 mg daily for COPD flares, and recently started bevacizumab. The bed is pale with adherent eschar and no granulation after three weeks of moist dressings. You do not escalate to daily enzymatic debridement as if this were a healable Stage 3. You treat glycemic control, smoking, and vascular referral as first-line wound interventions, flag steroids and antiangiogenic therapy as repair blockers, keep the heel offloaded and dry-stable if that is the ischemic plan, and document a not-healable wound until perfusion and host factors change. Anticoagulation, if she is on it, would further limit how aggressively you debride, but it is not the reason the bed cannot granulate—the PAD and oxygen story is.